The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

BACKGROUND: The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks. METHODS: 365 treatment-naïve patients with T2DM (HbA(1c) 7.0%...

Descripción completa

Detalles Bibliográficos
Autores principales: Frederich, Robert, McNeill, Robert, Berglind, Niklas, Fleming, Douglas, Chen, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541110/
https://www.ncbi.nlm.nih.gov/pubmed/22828124
http://dx.doi.org/10.1186/1758-5996-4-36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541110/
https://www.ncbi.nlm.nih.gov/pubmed/22828124
http://dx.doi.org/10.1186/1758-5996-4-36

Ejemplares similares